Skip to content

Preventing disease, maximizing longevity

New preventative health approaches are urgently required to reduce the global burden of complex chronic diseases. 

At PrecisionLife, we’ve discovered actively protective biology – mechanisms that naturally defend against disease in high-risk individuals – in over 60 complex diseases. These are a new class of drug target, enabling novel interventions to protect against disease and prevent disease progression.

This is the future of preventative healthcare. 

Actively protective biology drug targets

Helping people live longer, healthier lives

Increase healthspan

A key enabler for increasing the period of life spent in good health and reducing the global burden of chronic disease is finding cellular biology that is resilient to disease pressures.

Biological protection

The PrecisionLife Combinatorial Analytics & AI platform is uniquely able to identify actively protective, disease resilient mechanisms across all chronic diseases.

Disease prevention

Actively protective biology offers new drug targets to develop prophylactic drugs and therapeutic vaccines that delay onset of symptoms and prevent disease progression.

Detecting mechanisms that prevent disease in high-risk individuals

Our platform identifies combinations of features that contribute to reducing risk of disease in individuals who remain healthy even though their genomic profile suggests that they have high risk of developing disease.

These protective signatures can be used to identify novel drug targets, pharmacogenomic and therapeutic opportunities, and to better stratify patients by overall disease risk and mechanistic subtype.

Identifying protected cohorts


We screen healthy populations against our risk models to find cohorts enriched in actively protective factors – subgroups that have the risk signatures which would normally result in disease, but have not been affected.

Finding protective signatures


By eliminating the disease associated risk genes we find the genes unique to the protected cohort, which appear to be protecting against the development of the disease, even in patients at high risk.

Selecting protective targets


We then conduct biological analyses to identify and characterize key genes, potential drug targets, genetic interactions, pathways, and mechanisms of action represented by the protective disease signatures.

Actively Protective Biology schematic-min

 

CASE EXAMPLE

Actively protective biology in ALS

Amyotrophic lateral sclerosis (ALS) is a complex and fatal neurodegenerative disease with a strong genetic component.

Our ALS study discovered >30 risk-associated genes and 21 actively protective genes.

The protective genes include GRIP1, which has previously been associated with rare cases of ALS reversal, and MTRR, which codes for an enzyme that is central to the role of vitamin B12 within the cell.

Vitamin B12 has previously been explored in cellular, animal and clinical studies for its role in ALS, with promising outcomes and has now been approved for the treatment of ALS in Japan.

Actively protective biology highlights novel targets and pathways that provide natural disease resistance – offering new opportunities to develop precision therapies and even preventative interventions, opening the door to new strategies for delaying and preventing complex diseases before they take hold.

ALS actively protective biology-1-1

Identification of a replicated actively protective gene (MTRR) involved in uptake and function of cobalamin/vitamin B12 in ALS

PAPER

Actively Protective Combinatorial Analysis

A scalable new method for detecting variants that contribute to reduced disease prevalence in high-risk patients

Artificial Intelligence in the Life Sciences

 

 

Proactive, preventative healthcare

Our mechanostic tests and clinical decision support platform are transforming healthcare – identifying people who would benefit from specific interventions and enabling disease prevention – improving patient outcomes and reducing cost of care. 

Mechanostics®

Rapid, non-invasive tests to identify disease risk and guide therapy selection based on underlying disease mechanisms.

Clinical Decision Support

Interpretation of mechanostic tests with clinical reports that enable differential triage and early intervention.

Let's talk

Patients are counting on us

Be part of the future of disease prevention.
Partner with us to translate protective biology into breakthrough therapies.